Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Faricimab treatment outcomes with extended dosing and potential for Q20W intervals in DME: post hoc analysis of the 96-week phase 3 YOSEMITE/RHINE trials

Murtaza K Adam; Kara Gibson; Dawn Sim; Manuel Amador; Lauren Hill; Michael Singer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1756.

ARVO Annual Meeting Abstract June 2024

Extended treatment outcomes and the potential for Q20W dosing with faricimab in nAMD: a post hoc analysis of the pivotal TENAYA/LUCERNE trials

Philip Storey; Aude Ambresin; Adrian Hock Chaun Koh; Michael Singer; Lauren Hill; Aachal Kotecha; Philippe Margaron

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):254.

ARVO Annual Meeting Abstract June 2022

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study

Ramin Khoramnia; Tunde Peto; Simon R Taylor; Joao Paulo Castro de Sousa; Lauren Hill; Clare Bailey; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2182 – F0245.

ARVO Annual Meeting Abstract June 2022

Subretinal fibrosis in patients with choroidal neovascularization based on spectral-domain optical coherence tomography classification: findings from the HARBOR trial

Sean Adrean; Lauren Hill; Manuel J Amador-Patarroyo

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3869.

ARVO Annual Meeting Abstract June 2021

Effect of subretinal fluid (SRF) resolution on visual acuity in patients with neovascular age-related macular degeneration (nAMD)

David Ryan Lally; Lauren Hill; Min Tsuboi

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):338.

ARVO Annual Meeting Abstract June 2020

Anti-VEGF Resistant Subretinal Fluid is Associated With Reduced Risk of Macular Atrophy and Better Visual Acuity: Drug-Induced Choroidal New Vessel Homeostasis?

Marco A Zarbin; Ivo Stoilov; Lauren Hill

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3503.

ARVO Annual Meeting Abstract June 2020

Baseline diabetic retinopathy severity affects time to clinically meaningful improvements in diabetic retinopathy during ranibizumab treatment

Mitchell Goff; Lauren Hill; Karen Colbert; Ivo Stoilov; David Faber

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4035.

ARVO Annual Meeting Abstract July 2019

Pigment Epithelial Detachments Response to a Single Ranibizumab Injection: a HARBOR Subanalysis

Michael Javaheri; Lauren Hill; Avanti Ghanekar; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):75.

ARVO Annual Meeting Abstract July 2019

Patients ultra-responsive to ranibizumab: rates of ≥4-step improvement in diabetic retinopathy severity in DRCR.net Protocol S

Michael A. Klufas; Allen Chiang; Lauren Hill; Min Tsuboi; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5358.

ARVO Annual Meeting Abstract July 2019

Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial

Srinivas R Sadda; Avanti Ghanekar; Lauren Hill; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5189.

ARVO Annual Meeting Abstract July 2019

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 5-year Results of the RENO Study

Jonathan Dang; Arshad M. Khanani; Greggory Gahn; Micaela Koci; Nazrul Mojumder; Sylvia Phillips; Lauren Hill

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):101.

ARVO Annual Meeting Abstract July 2019

Visual Acuity Outcomes of Fellow Eyes Treated for New Onset Neovascular Age-Related Macular Degeneration in Patients in the RENO study

Nazrul Mojumder; Jonathan Dang; Arshad M. Khanani; Greggory Gahn; Micaela Koci; Sylvia Phillips; Lauren Hill

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):133.

ARVO Annual Meeting Abstract July 2018

Baseline factors associated with ≥ 2-step diabetic retinopathy (DR) severity improvement with ranibizumab (RBZ)

Dilsher Dhoot; Lauren Hill; Kathleen Tarnowski; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3592.

ARVO Annual Meeting Abstract July 2018

Baseline characteristics associated with good visual acuity outcomes in myopic choroidal neovascularization: results from the RADIANCE trial

Carolyn Pan; Diana V Do; Lauren Hill; Tatiana Ecoiffier; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):783.

ARVO Annual Meeting Abstract July 2018

Retrospective Evaluation of Neovascular Age-related Macular Degeneration Managed With Treat-And-Extend Regimen: 5-year Results of the RENO Study

Micaela Koci; Greggory M Gahn; Peter D Freeman; Lauren Hill; Sarah A Taylor; Aamir Aziz; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):810.

ARVO Annual Meeting Abstract July 2018

A Randomized, Double Masked, Prospective Clinical Trial To Evaluate Pain and Inflammation after Intravitreal Injection of Aflibercept or Ranibizumab in Patients with Diabetic Macular Edema: The SOLAR Study

Arshad M. Khanani; Greg L Cohen; Greggory M Gahn; Lauren Hill; Aamir Aziz; Micaela Koci; Peter D Freeman; Sarah A Taylor

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1475.

ARVO Annual Meeting Abstract June 2017

Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD

Michelle V Carle; Lauren Hill; Tatiana Ecoiffier; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):407.

ARVO Annual Meeting Abstract June 2017

The top 10 clinical pearls on treating pigment epithelial detachments due to neovascular age-related macular degeneration with ranibizumab in the HARBOR study

Arshad M Khanani; Lauren Hill; Lisa Tuomi

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):893.

ARVO Annual Meeting Abstract September 2016

Efficacy of ranibizumab therapy in eyes with neovascular AMD and pigment epithelial detachment (PED): a HARBOR subanalysis study

David Sarraf; Lauren Hill; Na Lu; Shamika Gune; Lisa Tuomi

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion

Charles Clifton Wykoff; Shamika Gune; Lauren Hill; Miranda Hemphill; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

1 2

Next 20 Results »

Advertisement